SeerPharma Blog listing page

For over 35 years, SeerPharma has been at the forefront of advancing Quality and GMP best practices within the pharmaceutical and medical device sectors. Our clients span the full product lifecycle—from early-stage clinical trials through to international market distribution.

The latest revision of ICH E6 (R3), finalised in January 2025 and enforced in Europe since 23 July 2025, marks a significant shift in clinical trial governance, moving beyond incremental updates to reflect modern trial practices and technologies. The guideline emphasises quality by design, risk-based proportionality, and clearer delineation of...